Evidence map›Paper›PMID 30989038›Full record

ReviewTissue engineering and regenerative medicine2019

Stem Cell-Based Therapies for Liver Diseases: An Overview and Update.

Jie Wang, Meiyan Sun, Wei Liu, Yan Li, Miao Li

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Tissue engineering and regenerative medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 79 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Stem cell-based therapeutic strategies for liver aging.Liver research (Beijing, China) · 2025
    Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Jie Wang1Department of Neurology, The China-Japan Union Hospital of Jilin University, No. 126 Xiantai Street, Changchun, 130033 Jilin China.
Meiyan SunMedical Examination College, Jilin Medical University, No. 5 Jilin Street, Changchun, Jilin, 132013 China.
Wei LiuMedical Examination College, Jilin Medical University, No. 5 Jilin Street, Changchun, Jilin, 132013 China.
Yan LiMedical Examination College, Jilin Medical University, No. 5 Jilin Street, Changchun, Jilin, 132013 China.
Miao Li3Department of Neurosurgery, The China-Japan Union Hospital of Jilin University, No. 126 Xiantai Street, Changchun, 130033 China.
Jilin Medical University · CNJilin University · CNUnion Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLiver disease is one of the top causes of death globally. Although liver transplantation is a very effective treatment strategy, the shortage of available donor organs, waiting list mortality, and high costs of surgery remain huge problems. Stem cells are undifferentiated cells that can differentiate into a variety of cell types. Scientists are exploring the possibilities of generating hepatocytes from stem cells as an alternative for the treatment of liver diseases.

methodsIn this review, we summarized the updated researches in the field of stem cell-based therapies for liver diseases as well as the current challenges and future expectations for a successful cell-based liver therapy.

resultsSeveral cell types have been investigated for liver regeneration, such as embryonic stem cells, induced pluripotent stem cells, liver stem cells, mesenchymal stem cells, and hematopoietic stem cells.

conclusionStem cell-based therapy could be a promising therapeutic method for patients with end-stage liver disease, which may alleviate the need for liver transplantation in the future.

Indexed as

AnimalsBiomarkersCell- and Tissue-Based TherapyCell DifferentiationDisease Models, AnimalEmbryonic Stem CellsGene ExpressionHematopoietic Stem CellsHepatocytesHumansInduced Pluripotent Stem CellsLiver DiseasesLiver RegenerationLiver TransplantationMesenchymal Stem CellsStem Cell TransplantationBiomarkersLiver diseaseLiver regenerationStem cell-based therapyStem cells

Identifiers

PMID30989038
PMCPMC6439111
OpenAlexW2915332416

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.